Last edition
News about
AbbVie to Acquire Apogee Therapeutics
AbbVie plans to acquire Apogee Therapeutics, expanding its immunology portfolio with a diverse pipeline of innovative therapies for dermatologic, respiratory, inflammatory, and immune-mediated diseases.
Japan Approves Wegovy for MASH
Wegovy subcutaneous injection has been approved in Japan for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), becoming the first approved therapy for the disease in the country.
Sanofi Secures Japan Approval for Subcutaneous Formulation of Sarclisa
Sanofi’s Sarclisa subcutaneous formulation has been approved in Japan for patients with multiple myeloma. The approval is supported by the Phase 3 IRAKLIA study and marks the second global approval after the EU.
Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal
Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.
Chugai Pharma's Avastin Secures Approval in Japan for Additional Indication
Chugai Pharma’s Avastin has received approval in Japan for an additional indication, becoming the world’s first therapeutic option for neurofibromatosis type 2. The approval is supported by positive phase 2 clinical study results.
Suven Life Sciences will showcase its differentiated CNS clinical portfolio at BIO International Convention 2026, featuring late-stage drug candidates for Alzheimer’s agitation, Major Depressive Disorder (MDD), narcolepsy, Parkinson’s-related cognitive impairment, and other CNS disorders.
Aurobindo Pharma USA Receives FTC Approval to Acquire Lannett Company
Aurobindo Pharma USA receives FTC approval to acquire Lannett Company in a USD 250 million deal. The transaction is expected to close before the end of June 2026.
Japan Approves Rituxan for Steroid-Dependent Nephrotic Syndrome in Adults
Rituxan (rituximab) IV 100 mg and 500 mg receives regulatory approval for adult-onset frequently relapsing or steroid-dependent nephrotic syndrome, with phase 3 data showing an 87.4 percent relapse-free rate at week 49.
Health Ministry Bans 16 Fixed Dose Combination Drugs in India
The Union Health Ministry has banned the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs in India, citing public health concerns and the need to ensure only safe, effective, and scientifically justified medicines remain available in the market.
Replicate Bioscience has been awarded a USD 3 million grant from the Gates Foundation to advance the development of self-replicating RNA-based tuberculosis vaccines, expanding its efforts to combat major infectious diseases including TB, HIV, malaria and rabies.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy